

Renal Cancer

Edited by

Professor Tim Eisen

University of Cambridge
Department of Oncology
Addenbrooke's Hospital
Cambridge, UK



OXFORD
UNIVERSITY PRESS

سرشناسه :	ایزن، تیم Eisen, Tim
عنوان و نام پدیدآور :	Renal cancer/ Tim Eisen.
مشخصات نشر :	تهران : ششم دانش، ۱۳۹۱ = ۲۰۱۲ م.
مشخصات ظاهری :	۱۲، ۱۰۸ ص.
فهرست :	oxford oncology library
شابک :	6-41-7124-964-978
وضعیت فهرستی نویسی :	فیها
پادداشت :	انگلیسی.
پادداشت :	افست از روی چاپ ۲۰۱۲ م. : oxford university press.
کوانتاسی عنوان :	رنال ...
موضوع :	کلیه‌ها - سرطان
رده بندی کنگره :	RC ۲۸۰/۴۹،۹ ۱۳۹۱
رده بندی دروی :	۶۱۸/۹۲۹۹۲۴۱
شماره کتابشناسی ملی :	۲۸۸۱۸۵۱



انتشارات ششم دانش

نام کتاب:	Renal Cancer
تالیف :	Tim Eisen
ناشر:	ششم دانش
نوبت چاپ:	چاپ اول، ۱۳۹۱
شمارگان:	۲۰۰ نسخه
لینوگرافی، چاپ و صحافی:	سید دانش
بها:	۷۵۰۰۰ ریال
شابک :	978-964-7124-41-6

آدرس: خیابان سمیه، بعد از خیابان واسر، ساختمان ۸۶، پلاک ۱۶۲، تلفن: ۸۸۲۸۸۸۷ شماره: ۸۸۲۳۳۳۲۲

پست الکترونیک: danesh.print@yahoo.com

OXFORD

UNIVERSITY PRESS

Great Clarendon Street, Oxford OX2 6DP

Oxford University Press is a department of the University of Oxford.
It furthers the University's objective of excellence in research, scholarship,
and education by publishing worldwide in

Oxford New York

Auckland Cape Town Dar es Salaam Hong Kong Karachi

Kuala Lumpur Madrid Melbourne Mexico City Nairobi

New Delhi Shanghai Taipei Toronto

With offices in

Argentina Austria Brazil Chile Czech Republic France Greece

Guatemala Hungary Italy Japan Poland Portugal Singapore

South Korea Switzerland Thailand Turkey Ukraine Vietnam

Oxford is a registered trade mark of Oxford University Press
in the UK and in certain other countries

Published in the United States

by Oxford University Press Inc., New York

© Oxford University Press, 2012

The moral rights of the authors have been asserted

Database right Oxford University Press (maker)

First published 2011

All rights reserved. No part of this publication may be reproduced,
stored in a retrieval system, or transmitted, in any form or by any means,
without the prior permission in writing of Oxford University Press,
or as expressly permitted by law, or under terms agreed with the appropriate
reprographics rights organization. Enquiries concerning reproduction
outside the scope of the above should be sent to the Rights Department,
Oxford University Press, at the address above

You must not circulate this book in any other binding or cover
and you must impose the same condition on any acquirer

British Library Cataloguing in Publication Data

Data available

Library of Congress Cataloging in Publication Data

Data available

Typeset by Newgen Imaging Systems (P) Ltd, Chennai, India

Printed in Great Britain

on acid-free paper by

Ashford Colour Press Ltd., Gosport, Hampshire

ISBN 978-0-19-956231-2

10 9 8 7 6 5 4 3 2 1

Contents

Preface vii

Abbreviations ix

Contributors xi

1	Aetiology and molecular basis of disease <i>Maxine Tran and Tim Eisen</i>	1
2	Radiological assessment <i>Aslam Sohaib</i>	9
3	Assessment of treatment options in renal cancer <i>Martin Gore and Sheeba Irshad</i>	19
4	The surgical approach <i>Arnaud Méjean and Marc-Olivier Timsit</i>	37
5	Interventional radiology <i>Khalid Enver and David Breen</i>	49
6	Systemic treatment: immunotherapy <i>Bernard Escudier, Marine Gross Goupil, Christophe Massard, and Karim Fizazi</i>	61
7	Systemic treatment: targeted therapies <i>Tanya Dorff and David Quinn</i>	73

- | | | |
|---|---|----|
| 8 | Palliative interventions | |
| | <i>Jessica Masterson, Michael J. Fisch, and Nizar M. Tannir</i> | 85 |
| 9 | Current trials in renal cell carcinoma | |
| | <i>Paul Nathan and Anup Vinayan</i> | 95 |

Index 105

Preface

The management of kidney cancer has developed enormously over the last decade. Advances in surgical techniques have recently been matched by a range of new drugs which target the tumour blood supply so crucial to the growth and spread of kidney cancer. With these advances have come new challenges for medical and nursing staff treating patients with kidney cancer. This book is a handy reference by international experts in the field. It covers the essential information needed to manage patients with kidney cancer in an easily accessible format. It will be of particular use to trainees in a number of medical, nursing and allied disciplines caring for patients with kidney cancer.

Abbreviations

3D	three-dimensional
5-FU	5-fluorouracil
AJCC	American Joint Committee on Cancer
AML	angiomyolipoma
BHD	Birt-Hogg-Dubé syndrome
CA IX	carbonic anhydrase IX
CCRC	clear cell renal carcinoma
CNS	central nervous system
CR	complete response
CT	computed tomography
DCs	dendritic cells
DFS	disease-free survival
DMSA	dimercaptosuccinic acid
ECOG	Eastern Cooperative Oncology Group
eGFR	estimation of glomerular filtration rate
EOTRC	European Organization for Research and Treatment of Cancer
FDA	Food and Drug Administration
FDG	fluorodeoxyglucose
Flt-3	foetal liver tyrosine kinase-3
Gp	glycoprotein
HFSR	hand-foot skin reaction
HIF	hypoxia-inducible factors
HL	hereditary leiomyomatosis
HLRCC	hereditary leiomyomatosis renal cell carcinoma
HSCT	hematopoietic stem cell transplantation
HSP	heat shock protein
IFN	interferon
IGA	image-guided ablation
IL-2	interleukin-2
IV	intravenous
IVC	inferior vena cava
MDRD	modification of diet in renal disease

MPR	multiplanar reformation
mRCC	metastatic renal cell carcinoma
MRC	Medical Research Council
MRI	magnetic resonance imaging
MSKCC	Memorial Sloan-Kettering Cancer Center
mTOR	mammalian target of rapamycin
NCCN	National Comprehensive Cancer Network
NCI	National Cancer Institute
NICE	National Institute for Health and Clinical Excellence
NK	natural killer (cells)
PD	progressive disease
PDGF	platelet-derived growth factor
PET	positron emission tomography
PFS	progression-free survival
PR	partial response
PRCC	papillary renal cell carcinoma
RCC	renal cell carcinoma
RECIST	response evaluation criteria in solid tumours
RFA	radiofrequency ablation
TAE	transarterial embolization
TARGET	The Treatment Approach in Renal Cancer Global Evaluation Trial
TBRR	tumour burden reduction rate
TGF α	transforming growth factor- α
TKIs	tyrosine kinase inhibitors
UISS	UCLA Integrated Staging System
VEGF	vascular endothelial growth factor
VHL	von Hippel-Lindau (disease)
WHO	World Health Organization

Contributors

David Breen

Southampton General Hospital
Southampton, UK

Tim Eisen

University of Cambridge
Department of Oncology
Addenbrooke's Hospital
Cambridge, UK

Khalid Enver

Southampton General Hospital
Southampton, UK

Bernard Escudier

Département de Médecine
Institut Gustave Roussy
Villejuif, France

Michael J. Fisch

Department of General Oncology
MD Anderson Cancer Center
Houston, Texas, USA

Karim Fizazi

Département de Médecine
Institut Gustave Roussy
Villejuif, France

Martin Gore

Royal Marsden Hospital
London, UK

Marine Gross Goupil

Département de Médecine
Institut Gustave Roussy
Villejuif, France

Sheeba Irshad

Medical Oncology Specialist Trainee
Royal Marsden Hospital
London, UK

Christophe Massard

Département de Médecine
Institut Gustave Roussy
Villejuif, France

Jessica Masterson

Division of Cancer Medicine, MD
Anderson Cancer Centre
Houston, Texas, USA

Arnaud Méjean

Department of Urology
Necker Hospital
Paris, France

Paul Nathan

Mount Vernon Cancer Centre
Northwood, UK

David Quinn

University of Southern
California
Los Angeles, California, USA

Aslam Sohaib

Department of Imaging
Royal Marsden Hospital
London, UK

Nizar M. Tannir

Department of Genitourinary
Medical Oncology
MD Anderson Cancer Center
Houston, Texas, USA

Marc-Olivier Timsit

Department of Urology
Necker Hospital
Paris, France

Maxine Tran

University of Cambridge
Department of Oncology
Addenbrooke's Hospital
Cambridge, UK

Anup Vinayan

Mount Vernon Cancer Centre
Northwood, UK